What the research shows
The CASTA trial randomized 1,070 patients with acute ischemic stroke to Cerebrolysin or placebo in addition to standard treatment. The prespecified overall comparison at 90 days found no significant difference. A signal in a subgroup with more severe strokes was exploratory and cannot replace that primary result. Read the CASTA clinical trial.
Documented formats
CASTA studied an intravenous infusion of the named preparation. Reproducing a single peptide found in the mixture would not reproduce the full test material.
Testing and purity
A complex preparation cannot be identified by one peptide sequence or one purity peak. Check the product, manufacturer, batch and methods used to characterize its composition before comparing studies.
How to read a batch reportQuestions about Cerebrolysin
Can a study identify which peptide in the mixture produced a result?
A trial comparing the whole preparation with placebo tests the mixture. It cannot isolate an individual component without additional experiments.
Why distinguish an overall result from a subgroup?
The primary comparison is the one the investigators planned to answer for the trial population. A subgroup can suggest a narrower question for a new study.